April 22, 2015 | The board of directors of Perrigo has rejected the offer made by Mylan NV to purchase its shares $29 billion. Perrigo has reportedly rejected the offer because it feels that it does not reflect the true value of Mylan’s company value and because it does not serve Perrigo’s shareholders’ interests. Simultaneously, Teva Pharmaceutical Industries has offered to purchase Mylan for nearly $41 billion, though Mylan has opposed take-over attempts in the past. Perrigo is the only non-Israeli company listed on the TA-25.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments